Daiichi Sankyo Co Ltd

Explore how Daiichi Sankyo’s pause on its ADC pipeline, the delay of a phase‑III readout with AstraZeneca, and the launch of an OTC emergency contraceptive reshape its strategy and market outlook.

EMA approves Enhertu as first‑line HER2‑positive breast cancer therapy, boosting Daiichi Sankyo’s oncology market, pricing strategy, and future M&A prospects.

Discover how Daiichi Sankyo’s 2026 J.P. Morgan Healthcare Conference strategy strengthens its R&D pipeline, tackles pricing pressures, and aligns with value‑based reimbursement models to boost global market access.

Discover how Daiichi Sankyo’s new partnerships with Organon and GENESIS Pharma bring oral PCSK9 and FLT3‑ITD inhibitors—Nilemdo and VANFLYTA—to key European markets, accelerating access for patients with statin‑intolerant dyslipidemia and AML.

Explore how Daiichi Sankyo’s new VANFLYTA partnership and Enhertu capacity expansion boost global oncology reach, supply resilience and revenue growth.

Explore how Daiichi Sankyo’s patent‑cliff strategy, M&A moves, and value‑based pricing shape its future growth and investor appeal.

Explore how Daiichi Sankyo’s oncology and immunotherapy strategy drives 10‑year NPV of $2.5 billion, tackles TNBC patent cliffs, and targets M&A for growth.

Discover how Daiichi Sankyo’s partnership with General Proximity’s OmniTAC™ and its new STING‑based program could unlock undruggable oncology targets like KRAS and MYC, advancing colorectal cancer treatment.

Discover Daiichi Sankyo’s Q2 2026 earnings insights—financial highlights, growth drivers, pipeline focus, and strategic plans that shape investor outlook.

Daiichi Sankyo’s oncology assets, particularly Enhertu, have shown promising results in late-stage clinical trials, driving significant investor interest and a surge in the company’s share price, with market analysts projecting substantial revenue g…